HC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $200

HC Wainwright & Co. analyst Swayampakula Ramakanth has maintained a Buy rating on Mirum Pharmaceuticals (NASDAQ: MIRM) and raised the price target from $195 to $200.